Oxaliplatin neurotoxicity of sensory transduction in rat proprioceptors

Journal of Neurophysiology

Volumn 106, Issue 2, 2011, Pages 704-709

  Bullinger, Katie L ^a   Nardelli, Paul ^a   Wang, Qingbo ^a   Rich, Mark M ^a   Cope, Timothy C ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Afferent; Chemotherapy; Electrophysiology; Muscle spindle; Neuropathy

Indexed keywords

OXALIPLATIN;

ACTION POTENTIAL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL ROOT; FEMALE; MUSCLE CONTRACTION; MUSCLE FORCE; MUSCLE LENGTH; MUSCLE STRETCHING; NERVE CELL; NERVE DEGENERATION; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPRIOCEPTION; RAT;

ANIMALS; FEMALE; MECHANOTRANSDUCTION, CELLULAR; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PROPRIOCEPTION; RANDOM ALLOCATION; RATS; RATS, WISTAR; SENSORY RECEPTOR CELLS;

EID: 80051486095     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00083.2011     Document Type: Article

References (23)

1. + channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25-32, 2000.
2. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34: 368, 2008.
3. Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anticancer agent that affects both Na and K channels in frog peripheral myelinated axons. Gen Physiol Biophys 25: 263-276, 2006.
4. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20: 3478-3483, 2002.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
6. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29: 21-33, 2002.
7. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293-2297, 2001.
8. Haftel VK, Bichler EK, Nichols TR, Pinter MJ, Cope TC. Movement reduces the dynamic response of muscle spindle afferents and motoneuron synaptic potentials in rat. J Neurophysiol 91: 2164-2171, 2004.
9. Haftel VK, Bichler EK, Wang QB, Prather JF, Pinter MJ, Cope TC. Central suppression of regenerated proprioceptive afferents. J Neurosci 25: 4733-4742, 2005.
10. Jamieson SM, Liu J, Connor B, McKeage MJ. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56: 391-399, 2005.
11. Johnson RD, Munson JB. Regenerating sprouts of axotomized cat muscle afferents express characteristic firing patterns to mechanical stimulation. J Neurophysiol 66: 2155-2158, 1991.
12. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 13: 2901-2907, 2006.
13. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatininduced neurotoxicity and the development of neuropathy. Muscle Nerve 32: 51-60, 2005.
14. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29: 387, 2004.
15. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38: 1-21, 2000.
16. Matthews PBC. The Structure of the Receptors. In: Mammalian Muscle Receptors and Their Central Actions. London: Edward Arnold, 1972, p. 1-59.
17. Novak KR, Nardelli P, Cope TC, Filatov G, Glass JD, Khan J, Rich MM. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest 119: 1150-1158, 2009.
18. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132: 2712-2723, 2009.
19. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59: 159-168, 2006.
20. Simon A, Shenton F, Hunter I, Banks RW, Bewick GS. Amiloride-sensitive channels are a major contributor to mechanotransduction in mammalian muscle spindles. J Physiol 588: 171-185, 2010.
21. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146: 1027-1039, 2005.
22. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20: 1767-1774, 2002.
23. Wu SN, Chen BS, Wu YH, Peng H, Chen LT. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology 30: 677-685, 2009.